{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 464382050
| IUPAC_name = 1-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1''H''-1,2,4-triazole-3-carboxamide
| image = Ribavirin.svg
| width = 200
| image2 = Ribavirin ball-and-stick.png
| width2 = 200

<!--Clinical data-->
| tradename = Copegus, Rebetol, Virazole
| Drugs.com = {{drugs.com|monograph|ribavirin}}
| MedlinePlus = a605018
| pregnancy_AU = X
| pregnancy_US = X
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral, inhalation

<!--Pharmacokinetic data-->
| bioavailability = 64%<ref name = TGA>{{cite web|title=PRODUCT INFORMATION REBETOL® (RIBAVIRIN) CAPSULES|work=TGA eBusiness Services|publisher=Merck Sharp & Dohme (Australia) Pty Limited|accessdate=23 February 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-02077-3|format=PDF|date=29 April 2013|archive-date=2017-08-16|archive-url=https://web.archive.org/web/20170816022733/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2012-PI-02077-3|dead-url=no}}</ref>
| protein_bound = 0%<ref name = TGA/>
| metabolism = Hepatic and intracellularly<ref name = TGA/> 
| elimination_half-life = 298 hours (multiple dose); 43.6 hours (single dose)<ref name = TGA/>
| excretion = Urine (61%), faeces (12%)<ref name = TGA/>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 36791-04-5
| ATC_prefix = J05
| ATC_suffix = AB04
| PubChem = 37542
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00811
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 34439
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 49717AWG6K
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00423
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1643
| NIAID_ChemDB = 000053
| PDB_ligand = RBV

<!--Chemical data-->
| C=8 | H=12 | N=4 | O=5 
| molecular_weight = 244.206
| smiles = OC[C@@H](O1)[C@@H](O)[C@@H](O)[C@@H]1N2N=C(C(N)=O)N=C2
| InChI = 1/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IWUCXVSUMQZMFG-AFCXAGJDSA-N
| synonyms = <small>1-(β-D-Ribofuranosyl)-1''H''-1,2,4-triazole-3-carboxamide</small>
}}

'''利巴韦林'''（{{lang-en|'''Ribavirin'''}}，俗称'''病毒唑'''），是一种[[抗病毒药|抗病毒药]]，属合成[[核苷|核苷]]类药，1970年由ICN制药公司Joseph T. Witkowski合成。对许多[[DNA病毒|DNA]]和[[RNA病毒|RNA病毒]]有抑制作用，其机理尚不清楚。[[美國食品藥物管理局|美國食品藥物管理局]]（FDA）只许可用于配合长效[[干扰素|干扰素]]治療[[丙肝|丙肝]]、[[人類呼吸道融合病毒|人類呼吸道融合病毒]]（RSV）{{notetag|1=疗效不佳，几乎弃用}}，和某些[[出血热|出血热]](WHO)的治疗。

== 滥用与副作用 ==
[[美国食品药品监督管理局|美国食品药品监督管理局]]明确指出利巴韦林不适合用来治疗[[流感|流感]]，并且严格明确适应症，而滥用利巴韦林来治疗各种病毒感染的情况在中国十分普遍。利巴韦林还具有致畸副作用，任何50岁以下女性应尽量避免使用利巴韦林，如需服用药物治疗必须采取2种或以上可靠避孕措施，如使用避孕套和口服避孕药，确保在最后一次使用利巴韦林6个月内未受孕。

==註解==
{{notefoot}}

== 参考文献 ==
{{Reflist}}

==外部連結==
*http://www.hepcassoc.org/news/article39.html{{Wayback|url=http://www.hepcassoc.org/news/article39.html |date=20200127062122 }}
*https://web.archive.org/web/20090611051955/http://jac.oxfordjournals.org/cgi/content/full/52/4/543
*http://www.hepatitiscentral.com/hcv/ribavirin/info.html{{Wayback|url=http://www.hepatitiscentral.com/hcv/ribavirin/info.html |date=20150416024018 }}
*https://web.archive.org/web/20041101184111/http://aidsinfo.nih.gov/drugs/htmldrug_tech.asp?int_id=0028
*http://www.jac.oxfordjournals.org/cgi/reprint/dki405v1
*[http://www.pegasys.com/about-pegasys/what-is-copegus.aspx Information on Ribavirin]{{Wayback|url=http://www.pegasys.com/about-pegasys/what-is-copegus.aspx |date=20120206024421 }}
{{-}}
{{抗病毒药物}}
{{抗DNA病毒药物}}
{{RNA antivirals|state=autocollapse}}
{{国家基本药物目录/抗微生物药}}

[[Category:抗病毒药物|Category:抗病毒药物]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:中华人民共和国国家基本药物|Category:中华人民共和国国家基本药物]]
[[Category:丙型肝炎|Category:丙型肝炎]]